Recent studies have suggested that p53 mutations may correlate with an increased tumor mutational burden (TMB) and a more immunogenic tumor microenvironment, although the efficacy of immunotherapy in microsatellite-stable (MSS) CRCs with TP53 mutations is yet to be fully explored [100,101,102]. This evidence concerns the gene TP53 and neoplasm.